by Plus Therapeutics | Aug 1, 2024 | Uncategorized
You’re Invited to our symposium “Emerging Novel Diagnostic and Therapeutic Approaches for Leptomeningeal Metastases,” presented at the SNO/ASCO CNS conference in Denver. More information & RSVP: https://bit.ly/4bM777e “Emerging Novel...
by Plus Therapeutics | Jul 25, 2024 | Uncategorized
UPCOMING PRESENTATIONS: Plus Therapeutics Showcases Leptomeningeal Metastases Programs at 2024 SNO/ASCO Conference and scheduled to present new data, highlighting progress in its therapeutics and diagnostics programs for Leptomeningeal Metastases Read the full details...
by Plus Therapeutics | Jul 24, 2024 | Uncategorized
“Radiopharmaceutical therapy (RPT) is emerging as a safe and effective targeted approach to treating many types of cancer. In RPT, radiation is systemically or locally delivered. To learn more about emerging developments, Digital Journal spoke with Marc Hedrick,...
by Plus Therapeutics | Jul 2, 2024 | Uncategorized
Join us at the Gordon Research Conference: Radionuclide Theranostics for the Management of Cancer, being held July 7-12 in Newry, Maine, as Plus Therapeutics takes the stage. Presentation by Melissa Moore, Ph.D. Press Release: https://bit.ly/PSTV_PR...
by Plus Therapeutics | Jun 28, 2024 | Uncategorized
We are proud to support @glioblastomaakagbm podcast by @glioblastomaresearch! Listen again to the episode “Power and Precision with Plus Therapeutics”: https://spoti.fi/3W4O5Dl In their latest episode, they are joined by Holly Gainsboro, a grief specialist...
by Plus Therapeutics | Jun 18, 2024 | Uncategorized
Plus Therapeutics presented data on its novel radioisotope rhenium-186 at the annual meeting of the Society of Nuclear Medicine & Molecular Imaging (SNMMI) in Toronto. Link to presentation: https://bit.ly/4bd9GyB An oral presentation titled, “Radiation Absorbed...
Recent Comments